The correction of RyR2 dysfunction in both point mutation carriers and HF patients and the development of novel therapeutic strategies is currently the focus of a much effort, particularly methods to prevent the onset of fatal arrhythmia. The gene discussed is RYR2; the disease is hydrops fetalis.